Filing Flows › Comparisons › LYEL vs PULM
Lyell Immunopharma vs Pulmatrix: LYEL and PULM compared
Lyell Immunopharma is the larger company: $3K of revenue in its latest quarter (Q3 2026) against $3K for Pulmatrix (Q4 2024). Lyell Immunopharma is growing faster (-80% against -100% a year earlier).
Where the money goes: LYEL and PULM
Lyell Immunopharma (LYEL) · Q3 2026
Lyell Immunopharma, Q3 2026: revenue $3K (-80% year over year), net loss $45.5M, operating cash flow −$34.6M. The chart follows the revenue to costs, profit and cash.
Pulmatrix (PULM) · Q4 2024
Pulmatrix, Q4 2024: revenue $3K (-100% year over year), net loss $2.0M, operating cash flow −$1.3M. The chart follows the revenue to costs, profit and cash.
| Lyell Immunopharma (LYEL) | Pulmatrix (PULM) | |
|---|---|---|
| Latest quarter | Q3 2026 | Q4 2024 |
| Revenue | $3K | $3K |
| Revenue growth, Y/Y | -80% | -100% |
| Operating margin | n/m | n/m |
| Net earnings | −$45.5M | −$2.0M |
| Operating cash flow | −$34.6M | −$1.3M |
Questions
Which is bigger, Lyell Immunopharma or Pulmatrix?
Lyell Immunopharma is the larger company: $3K of revenue in its latest quarter (Q3 2026) against $3K for Pulmatrix (Q4 2024).
Is Lyell Immunopharma or Pulmatrix growing faster?
Lyell Immunopharma is growing faster (-80% against -100% a year earlier).
More: Lyell Immunopharma earnings · how Lyell Immunopharma makes money · Pulmatrix earnings · how Pulmatrix makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Nov 4, 2026; 10-K filed Mar 21, 2025). Fiscal quarters can end on different dates. Not investment advice.